Indivior PLC (LON:INDV) hit a new 52-week low on Wednesday . The company traded as low as GBX 215 ($2.80) and last traded at GBX 215 ($2.80), with a volume of 4565887 shares trading hands. The stock had previously closed at GBX 257.40 ($3.35).

A number of equities research analysts have weighed in on the stock. Numis Securities reiterated a “buy” rating on shares of Indivior in a research note on Thursday. Citigroup reduced their price objective on Indivior from GBX 365 ($4.75) to GBX 350 ($4.56) and set a “neutral” rating for the company in a research note on Thursday, July 26th. Morgan Stanley reduced their price objective on Indivior from GBX 455 ($5.93) to GBX 398 ($5.18) and set an “equal weight” rating for the company in a research note on Tuesday, June 19th. Jefferies Financial Group restated a “buy” rating and issued a GBX 630 ($8.21) price objective on shares of Indivior in a research note on Friday, June 15th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a GBX 550 ($7.16) price objective (up from GBX 540 ($7.03)) on shares of Indivior in a research note on Friday, June 15th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of GBX 444.60 ($5.79).

Indivior Company Profile (LON:INDV)

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.

Featured Article: Tariff

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.